# A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Study · id `cardio:ct-nct03626688` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03626688](<https://clinicaltrials.gov/study/NCT03626688>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03626688

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 687 participants.

## Technical summary

Registry record NCT03626688. Randomized; quadruple masking; primary purpose treatment. Start 2019-01-24 (actual); primary completion 2025-12-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 687 participants (enrolled count; ClinicalTrials.gov record NCT03626688, source copy `cardio:ctgov-nct03626688-2026-06-16`, retrieved 2026-10-31)
- Started: 2019-01-24 (actual) (ClinicalTrials.gov record NCT03626688, source copy `cardio:ctgov-nct03626688-2026-06-16`, retrieved 2026-10-31)
- Primary completion: 2025-12-31 (actual) (ClinicalTrials.gov record NCT03626688, source copy `cardio:ctgov-nct03626688-2026-06-16`, retrieved 2026-10-31)
- Completion: 2025-12-31 (actual) (ClinicalTrials.gov record NCT03626688, source copy `cardio:ctgov-nct03626688-2026-06-16`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Croatia; Czechia; Denmark; France; Germany; Greece; Hungary; Israel; Italy; Mexico; Netherlands; Poland; Portugal; Romania; Serbia; Singapore; South Korea; Spain; Sweden; Taiwan; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT03626688, source copy `cardio:ctgov-nct03626688-2026-06-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03626688-2026-06-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
- Condition: PAH
- Condition: Pulmonary Hypertension
- Condition: Pulmonary Arterial Hypertension
- Condition: Hypertension
- Condition: Connective Tissue Diseases
- Condition: Familial Primary Pulmonary Hypertension
- Condition: Vascular Diseases
- Condition: Cardiovascular Diseases
- Condition: Hypertension, Pulmonary
- Condition: Lung Diseases
- Condition: Respiratory Tract Disease
- Intervention (Drug): Ralinepag
- Intervention (Drug): Placebo
- Lead sponsor: United Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: United Therapeutics (`cardio:org-united-therapeutics`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study (`cardio:pubmed-42520828`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ba2c727294fe8b81976b0e7c76502b1fab440b9fe4ff2b35c41466cc10514746
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
